Published in Cardiorenal Med on January 17, 2011
The pathophysiology of hypertension in patients with obesity. Nat Rev Endocrinol (2014) 2.13
Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism (2013) 1.27
Molecular and metabolic mechanisms of cardiac dysfunction in diabetes. Life Sci (2012) 1.21
Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats. Endocrinology (2013) 1.15
Insulin resistance and heart failure: molecular mechanisms. Heart Fail Clin (2012) 1.07
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. Am J Physiol Heart Circ Physiol (2014) 1.04
Overweight female rats selectively breed for low aerobic capacity exhibit increased myocardial fibrosis and diastolic dysfunction. Am J Physiol Heart Circ Physiol (2012) 1.01
The Impact of Overnutrition on Insulin Metabolic Signaling in the Heart and the Kidney. Cardiorenal Med (2011) 1.01
Fructose and uric acid: is there a role in endothelial function? Curr Hypertens Rep (2014) 1.01
Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity. Metabolism (2014) 0.98
Adipose tissue immune response: novel triggers and consequences for chronic inflammatory conditions. Inflammation (2014) 0.98
Uric Acid - key ingredient in the recipe for cardiorenal metabolic syndrome. Cardiorenal Med (2013) 0.95
Over-nutrition and metabolic cardiomyopathy. Metabolism (2012) 0.94
Physical Activity in the Prevention of Chronic Kidney Disease. Cardiorenal Med (2011) 0.87
DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat. Obesity (Silver Spring) (2014) 0.87
Prenatal Programming and Epigenetics in the Genesis of the Cardiorenal Syndrome. Cardiorenal Med (2011) 0.87
Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives. Endocrinol Metab Clin North Am (2013) 0.86
DPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes. Cardiorenal Med (2013) 0.86
Cardiorenal metabolic syndrome and cardiometabolic risks in minority populations. Cardiorenal Med (2013) 0.86
Obesity and the Cardiorenal Metabolic Syndrome: Therapeutic Modalities and Their Efficacy in Improving Cardiovascular and Renal Risk Factors. Cardiorenal Med (2012) 0.86
Dietary phthalates and low-grade albuminuria in US children and adolescents. Clin J Am Soc Nephrol (2013) 0.85
Insulin resistance and skeletal muscle vasculature: significance, assessment and therapeutic modulators. Cardiorenal Med (2014) 0.85
Left ventricular global longitudinal strain is associated with cardiovascular risk factors and arterial stiffness in chronic kidney disease. BMC Nephrol (2015) 0.84
Cardiac insulin resistance and microRNA modulators. Exp Diabetes Res (2011) 0.84
Phosphate Metabolism in Cardiorenal Metabolic Disease. Cardiorenal Med (2011) 0.84
Cardiorenal metabolic syndrome and diabetic cognopathy. Cardiorenal Med (2013) 0.82
The effects of environmental chemicals on renal function. Nat Rev Nephrol (2015) 0.81
Obesity does not lead to imbalance between myocardial phospholamban phosphorylation and dephosphorylation. Arq Bras Cardiol (2014) 0.81
Estrogen and mitochondria function in cardiorenal metabolic syndrome. Prog Mol Biol Transl Sci (2014) 0.79
Use of Metformin in Patients with Kidney and Cardiovascular Diseases. Cardiorenal Med (2011) 0.78
Basic science: Pathophysiology: the cardiorenal metabolic syndrome. J Am Soc Hypertens (2014) 0.78
Phosphoprotein Phosphatase PP2A Regulation of Insulin Receptor Substrate 1 and Insulin Metabolic Signaling. Cardiorenal Med (2012) 0.78
Obesity and heart failure as a mediator of the cerebrorenal interaction. Contrib Nephrol (2013) 0.78
Evidence-based hypertension treatment in patients with diabetes. J Clin Hypertens (Greenwich) (2011) 0.78
Pigmented rice bran and plant sterol combination reduces serum lipids in overweight and obese adults. J Am Coll Nutr (2014) 0.77
Childhood-Adolescent Obesity in the Cardiorenal Syndrome: Lessons from Animal Models. Cardiorenal Med (2011) 0.77
Effect of the FTO rs9930506 Polymorphism on the Main Comorbidities of the Cardiorenal Metabolic Syndrome in an Elderly Spanish Cohort. Cardiorenal Med (2014) 0.75
Mitochondrial functional impairment in response to environmental toxins in the cardiorenal metabolic syndrome. Arch Toxicol (2015) 0.75
TT genotype of rs2941484 in the human HNF4G gene is associated with hyperuricemia in Chinese Han men. Oncotarget (2017) 0.75
Improved Identification and Antihypertension Pharmacotherapy in Cardiorenal Metabolic Syndrome: Focus on Racial/Ethnic Minorities, Olmesartan Medoxomil, and Combination Therapy. Cardiorenal Med (2012) 0.75
Uric acid promotes vascular stiffness, maladaptive inflammatory responses and proteinuria in western diet fed mice. Metabolism (2017) 0.75
Prevalence of overweight and obesity in the United States, 1999-2004. JAMA (2006) 72.59
Prevalence of chronic kidney disease in the United States. JAMA (2007) 38.98
Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2009) 27.89
Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med (2006) 17.13
High body mass index for age among US children and adolescents, 2003-2006. JAMA (2008) 16.00
Obesity and the metabolic syndrome in children and adolescents. N Engl J Med (2004) 13.99
Body mass index and risk for end-stage renal disease. Ann Intern Med (2006) 7.56
The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med (2004) 5.45
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr (2007) 5.28
A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol (2005) 4.95
Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone. J Am Coll Cardiol (1997) 4.40
Sugar-sweetened beverages and incidence of type 2 diabetes mellitus in African American women. Arch Intern Med (2008) 4.03
Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol (2005) 3.96
Body mass index and mortality: a meta-analysis based on person-level data from twenty-six observational studies. Ann Epidemiol (2005) 3.92
Salt intake is related to soft drink consumption in children and adolescents: a link to obesity? Hypertension (2008) 3.68
Obesity and risk for chronic renal failure. J Am Soc Nephrol (2006) 3.67
The metabolic syndrome in overweight Hispanic youth and the role of insulin sensitivity. J Clin Endocrinol Metab (2004) 3.20
Glomerular hyperfiltration: a new marker of metabolic risk. Kidney Int (2007) 3.17
Race/ethnic issues in obesity and obesity-related comorbidities. J Clin Endocrinol Metab (2004) 3.03
Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum (2008) 2.91
Marked association between obesity and glomerular hyperfiltration: a cross-sectional study in an African population. Am J Kidney Dis (2010) 2.71
The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol (2003) 2.66
Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension (2006) 2.59
Sugar-sweetened soda consumption, hyperuricemia, and kidney disease. Kidney Int (2009) 2.48
Socioeconomic status and the incidence of ESRD. Am J Kidney Dis (2008) 2.48
Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol (2002) 2.48
The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. JAMA (1991) 2.44
Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int (2004) 2.44
Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail (2002) 2.18
Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. Am J Physiol Renal Physiol (2006) 1.94
Is low birth weight an antecedent of CKD in later life? A systematic review of observational studies. Am J Kidney Dis (2009) 1.94
Obesity as a cardiovascular risk factor. Am J Med (2003) 1.86
Low birth weights contribute to high rates of early-onset chronic renal failure in the Southeastern United States. Arch Intern Med (2000) 1.70
Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Can J Gastroenterol (2008) 1.68
Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J (2005) 1.65
Fructose, but not dextrose, accelerates the progression of chronic kidney disease. Am J Physiol Renal Physiol (2007) 1.65
Obesity, glomerular hyperfiltration, and the surface area correction. Am J Kidney Dis (2010) 1.64
Adverse renal consequences of obesity. Am J Physiol Renal Physiol (2008) 1.62
Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat. Am J Physiol Endocrinol Metab (2007) 1.46
Type 2 diabetes mellitus: managing hemoglobin A(1c) and beyond. South Med J (2010) 1.41
Metabolic syndrome and the development of CKD in American Indians: the Strong Heart Study. Am J Kidney Dis (2008) 1.34
Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. J Am Soc Nephrol (2006) 1.33
Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension (2010) 1.32
Alterations in fatty acid kinetics in obese adolescents with increased intrahepatic triglyceride content. Obesity (Silver Spring) (2008) 1.27
Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis (2003) 1.26
Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int (2006) 1.22
Sugary soda consumption and albuminuria: results from the National Health and Nutrition Examination Survey, 1999-2004. PLoS One (2008) 1.20
Metabolic syndrome, proteinuria, and the risk of progressive CKD in hypertensive African Americans. Am J Kidney Dis (2008) 1.15
Metabolic risk factors and renal disease. Kidney Int (2007) 1.14
Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension (2006) 1.13
Abdominal obesity and the spectrum of global cardiometabolic risks in US adults. Int J Obes (Lond) (2008) 1.11
Oxidative stress and inflammatory mediators contribute to endothelial dysfunction in high-fat diet-induced obesity in mice. J Hypertens (2010) 1.10
Resistance to the nitric oxide/cyclic guanosine 5'-monophosphate/protein kinase G pathway in vascular smooth muscle cells from the obese Zucker rat, a classical animal model of insulin resistance: role of oxidative stress. Endocrinology (2007) 1.09
Cardiomyocyte-restricted overexpression of endothelial nitric oxide synthase (NOS3) attenuates beta-adrenergic stimulation and reinforces vagal inhibition of cardiac contraction. Circulation (2004) 1.05
National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int (2010) 1.04
Microalbuminuria, central adiposity and hypertension in the non-diabetic urban population of the MONICA Augsburg survey 1994/95. J Hum Hypertens (2001) 1.04
Carbonated beverages and chronic kidney disease. Epidemiology (2007) 0.98
Relation between Childhood Obesity and Adult Cardiovascular Risk. Int J Pediatr Endocrinol (2009) 0.98
Direct, progressive association of cardiovascular risk factors with incident proteinuria: results from the Korea Medical Insurance Corporation (KMIC) study. Arch Intern Med (2005) 0.96
Dysglycemia predicts cardiovascular and kidney disease in the Kidney Early Evaluation Program. J Clin Hypertens (Greenwich) (2010) 0.94
Cardiac hypertrophy, substrate utilization and metabolic remodelling: cause or effect? Clin Exp Pharmacol Physiol (2006) 0.93
High-fructose feeding of streptozotocin-diabetic rats is associated with increased cataract formation and increased oxidative stress in the kidney. Br J Nutr (2000) 0.92
The effect of bariatric surgery on adipocytokines, renal parameters and other cardiovascular risk factors in severe and very severe obesity: 1-year follow-up. Clin Nutr (2006) 0.91
Therapeutic strategies for heart failure in cardiorenal syndromes. Am J Kidney Dis (2010) 0.89
Glomerular sclerosis in patients with massive obesity. Am J Nephrol (1985) 0.88
Reversible obesity-related glomerulopathy following weight reduction. Med J Aust (2006) 0.86
Metabolic syndrome resolution in children and adolescents after 10 weeks of weight loss. J Cardiometab Syndr (2008) 0.84
Pediatric obesity guidelines released. JAMA (2008) 0.83
Interrelationship of left ventricular mass, systolic function and diastolic filling in normotensive morbidly obese patients. Int J Obes Relat Metab Disord (1995) 0.82
Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med (2009) 2.25
Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med (Berl) (2010) 1.90
Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure. Am J Physiol Lung Cell Mol Physiol (2002) 1.76
Mechanism of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats. J Hypertens (2003) 1.71
Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol (2007) 1.71
Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol (2007) 1.68
Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species and therapeutic approaches. Oxid Med Cell Longev (2010) 1.47
Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat. Am J Physiol Endocrinol Metab (2007) 1.46
Redox control of renal function and hypertension. Antioxid Redox Signal (2008) 1.45
No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease. Kidney Int (2013) 1.38
Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension (2010) 1.32
Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology (2007) 1.31
Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol (2006) 1.30
Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension (2008) 1.23
Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab (2008) 1.22
Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology (2008) 1.21
Obesity and insulin resistance induce early development of diastolic dysfunction in young female mice fed a Western diet. Endocrinology (2013) 1.19
Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am J Physiol Heart Circ Physiol (2009) 1.18
Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology (2009) 1.18
Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats. Endocrinology (2013) 1.15
Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat. Am J Physiol Endocrinol Metab (2008) 1.15
Role of matrix metalloproteinase-9 in endothelial apoptosis in chronic heart failure in mice. J Appl Physiol (1985) (2005) 1.14
Oxidative stress contributes to pulmonary hypertension in the transgenic (mRen2)27 rat. Am J Physiol Heart Circ Physiol (2008) 1.12
Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities. Am J Physiol Regul Integr Comp Physiol (2011) 1.12
Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. Endocrinology (2007) 1.11
Attenuation of endocrine-exocrine pancreatic communication in type 2 diabetes: pancreatic extracellular matrix ultrastructural abnormalities. J Cardiometab Syndr (2008) 1.06
Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin. Am J Nephrol (2011) 1.03
Nebivolol attenuates redox-sensitive glomerular and tubular mediated proteinuria in obese rats. Endocrinology (2010) 1.03
Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells. Am J Nephrol (2007) 1.01
Overweight female rats selectively breed for low aerobic capacity exhibit increased myocardial fibrosis and diastolic dysfunction. Am J Physiol Heart Circ Physiol (2012) 1.01
The Impact of Overnutrition on Insulin Metabolic Signaling in the Heart and the Kidney. Cardiorenal Med (2011) 1.01
GABA receptors ameliorate Hcy-mediated integrin shedding and constrictive collagen remodeling in microvascular endothelial cells. Cell Biochem Biophys (2006) 1.00
Cardioprotective role of sodium thiosulfate on chronic heart failure by modulating endogenous H2S generation. Pharmacology (2008) 1.00
Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease. Metabolism (2009) 1.00
Proximal tubule microvilli remodeling and albuminuria in the Ren2 transgenic rat. Am J Physiol Renal Physiol (2006) 0.99
Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury. Am J Nephrol (2007) 0.99
Obesity-related alterations in cardiac lipid profile and nondipping blood pressure pattern during transition to diastolic dysfunction in male db/db mice. Endocrinology (2012) 0.99
Inhibition of nitric oxide synthase evokes central sympatho-excitation in healthy humans. J Physiol (2009) 0.98
Hypertension and insulin resistance. Hypertension (2009) 0.98
Cardiovascular disease in chronic kidney disease: data from the Kidney Early Evaluation Program (KEEP). Curr Diab Rep (2011) 0.98
The cardiometabolic syndrome as a cardiovascular risk factor. Am J Med Sci (2005) 0.95
Doxycycline ameliorates ischemic and border-zone remodeling and endothelial dysfunction after myocardial infarction in rats. J Heart Lung Transplant (2004) 0.94
Obesity, Diabetes, the Cardiorenal Syndrome, and Risk for Cancer. Cardiorenal Med (2012) 0.94
Role of nitric oxide in matrix remodeling in diabetes and heart failure. Heart Fail Rev (2003) 0.93
The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease. Curr Diab Rep (2010) 0.93
Prevention of obesity-induced renal injury in male mice by DPP4 inhibition. Endocrinology (2014) 0.93
Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: paying homage to the podocyte. Am J Nephrol (2005) 0.93
Indices of obesity and cardiometabolic risk. Hypertension (2011) 0.92
The key role of insulin resistance in the cardiometabolic syndrome. Am J Med Sci (2005) 0.92
Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. Am J Hypertens (2012) 0.91
Nebivolol attenuates maladaptive proximal tubule remodeling in transgenic rats. Am J Nephrol (2010) 0.90
Retinal redox stress and remodeling in cardiometabolic syndrome and diabetes. Oxid Med Cell Longev (2010) 0.89
Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. Am J Physiol Renal Physiol (2009) 0.89
Nonalcoholic steatohepatitis and the cardiometabolic syndrome. J Cardiometab Syndr (2006) 0.88
Antihypertensive medications and their effects on lipid metabolism. Curr Diab Rep (2008) 0.88
Cardiometabolic syndrome and chronic kidney disease: what is the link? J Cardiometab Syndr (2006) 0.87
Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat. Am J Physiol Heart Circ Physiol (2012) 0.87
Pancreatic renin-angiotensin-aldosterone system in the cardiometabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr (2008) 0.87
DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat. Obesity (Silver Spring) (2014) 0.87
Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2)27 rat. Am J Physiol Heart Circ Physiol (2010) 0.87
Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat. Regul Pept (2012) 0.87
Possible Mechanisms of Local Tissue Renin-Angiotensin System Activation in the Cardiorenal Metabolic Syndrome and Type 2 Diabetes Mellitus. Cardiorenal Med (2011) 0.87
Prenatal Programming and Epigenetics in the Genesis of the Cardiorenal Syndrome. Cardiorenal Med (2011) 0.87
Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives. Endocrinol Metab Clin North Am (2013) 0.86
Association of race and body mass index with ESRD and mortality in CKD stages 3-4: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis (2012) 0.86
Acute Cardiac Tamponade: An Unusual Cause of Acute Renal Failure. Cardiorenal Med (2012) 0.86
DPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes. Cardiorenal Med (2013) 0.86
Hypertension in Cardiovascular and Kidney Disease. Cardiorenal Med (2011) 0.85
The Association between Parathyroid Hormone Levels and the Cardiorenal Metabolic Syndrome in Non-Diabetic Chronic Kidney Disease. Cardiorenal Med (2011) 0.85
Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vasc Health Risk Manag (2009) 0.85
The association of parathyroid hormone with ESRD and pre-ESRD mortality in the Kidney Early Evaluation Program. J Clin Endocrinol Metab (2012) 0.84
Regulation of Overnutrition-Induced Cardiac Inflammatory Mechanisms. Cardiorenal Med (2012) 0.84
Redox imbalance in diabetes. Antioxid Redox Signal (2007) 0.84
Novel role for the incretins in blood pressure regulation. Curr Opin Nephrol Hypertens (2012) 0.84
Renin-angiotensin-aldosterone system-mediated redox effects in chronic kidney disease. Transl Res (2009) 0.83
Resistant hypertension in the high-risk metabolic patient. Curr Diab Rep (2011) 0.83
Hypertension and the cardiometabolic syndrome. J Clin Hypertens (Greenwich) (2005) 0.83
Nebivolol improves insulin sensitivity in the TGR(Ren2)27 rat. Metabolism (2011) 0.83
The Association between Parathyroid Hormone Levels and Hemoglobin in Diabetic and Nondiabetic Participants in the National Kidney Foundation's Kidney Early Evaluation Program. Cardiorenal Med (2013) 0.82
The role of beta-cell dysfunction in the cardiometabolic syndrome. J Cardiometab Syndr (2006) 0.82
Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling. Metabolism (2013) 0.82
Expression of matrix metalloproteinase activity in idiopathic dilated cardiomyopathy: a marker of cardiac dilatation. Mol Cell Biochem (2004) 0.82
Hypertension in people with diabetes and the metabolic syndrome: pathophysiologic insights and therapeutic update. Curr Diab Rep (2007) 0.82
Overnutrition and the Cardiorenal Syndrome: Use of a Rodent Model to Examine Mechanisms. Cardiorenal Med (2011) 0.82
Hyponatremia, arginine vasopressin dysregulation, and vasopressin receptor antagonism. Am J Nephrol (2006) 0.82
The Role of Team-Based Care Involving Pharmacists to Improve Cardiovascular and Renal Outcomes. Cardiorenal Med (2012) 0.82
Mineralocorticoid receptor-dependent proximal tubule injury is mediated by a redox-sensitive mTOR/S6K1 pathway. Am J Nephrol (2011) 0.81
Metabolic derangements in the insulin-resistant heart. J Cardiometab Syndr (2006) 0.81
Nebivolol in obese and non-obese hypertensive patients. J Clin Hypertens (Greenwich) (2009) 0.79